Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors in both preclinical and clinical settings. In light of the recent discovery of tumor-init...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Douglas D., Zhang, Cathy C., Gu, Yin, Jani, Jitesh P., Cao, Joan, Tsaparikos, Konstantinos, Yuan, Jing, Thiel, Melissa, Jackson-Fisher, Amy, Zong, Qing, Lappin, Patrick B., Hayashi, Tomoko, Schwab, Richard B., Wong, Anthony, John-Baptiste, Annette, Bagrodia, Shubha, Los, Geritt, Bender, Steve, Christensen, James, VanArsdale, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695076/
https://www.ncbi.nlm.nih.gov/pubmed/23826249
http://dx.doi.org/10.1371/journal.pone.0067258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3695076/
https://www.ncbi.nlm.nih.gov/pubmed/23826249
http://dx.doi.org/10.1371/journal.pone.0067258

Ejemplares similares